معرفی
Jonathan Zippin is an Associate Professor of Dermatology at Weill Cornell Medical College, where he has been on faculty since 2018. His research focuses on fundamental signaling pathways responsible for cellular growth in the skin, with particular emphasis on the role of soluble adenylyl cyclase (sAC) in melanocyte biology, pigmentation, and skin cancer development. Dr. Zippin maintains active collaborations with researchers at the Sloan Kettering Institute and participates in the Tri-Institutional training programs.
Dr. Zippin's educational background includes:
- M.D. from Weill Cornell Medical College, Cornell University (2006)
- Ph.D. from Weill Cornell Graduate School of Medical Sciences (2005)
- B.S. from Cornell University (1998)
Dr. Zippin's research program centers on understanding how soluble adenylyl cyclase (sAC), a novel source of cAMP discovered approximately 15 years ago, regulates cellular processes in the skin. Unlike other adenylyl cyclases, sAC is present throughout the cell including the nucleus and mitochondria. His laboratory investigates how sAC signaling affects melanosomal pH, melanin synthesis, and the development of skin conditions including psoriasis, verruca vulgaris, and skin cancer. A significant portion of his work examines how dysregulation of sAC contributes to melanomagenesis and how targeting this pathway might yield novel therapeutic approaches for pigmentary disorders and melanoma.
Analysis of Dr. Zippin's recent publication record reveals a strong focus on the intersection of cAMP signaling, melanocyte biology, and skin cancer. His work demonstrates how distinct cAMP microdomains differentially regulate melanosomal pH and pigmentation, with implications for understanding both normal skin physiology and disease states. His research spans basic molecular mechanisms to clinical applications, including therapeutic development targeting sAC for conditions ranging from albinism to melanoma. Notably, his team has developed methods to modulate melanosome pH and melanin levels, with potential applications in treating pigmentary disorders.
Dr. Zippin has secured significant research funding to support his work, including:
- The PanAmerican Society for Pigment Cell Research (PASPCR) 25th annual conference (2024-2025)
- Evaluation of Vitamin C in melanocytes funded by L'Oréal USA (2023-2026)
- Development of soluble adenylyl cyclase inhibitors to improve ocular pigmentation funded by the National Organization for Albinism and Hypopigmentation (2023-2026)
- Mechanisms Of cAMP-Dependent Regulation Of Melanosome pH funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (2021-2026)
Dr. Zippin collaborates extensively with colleagues including Dr. Zuhal Eraslan (3 joint grants), Dr. Qiuying Chen, and Dr. Steven S. Gross. His laboratory focuses on understanding the subcellular localization of soluble adenylyl cyclase as a potential diagnostic tool for melanocytic proliferations and investigating how sAC signaling pathways might be targeted therapeutically for skin conditions ranging from psoriasis to melanoma.
